|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM160487366 |
| 003 |
DE-627 |
| 005 |
20231223090210.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0535.xml
|
| 035 |
|
|
|a (DE-627)NLM160487366
|
| 035 |
|
|
|a (NLM)16453919
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Clark, Wayne L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Exenatide. From the Gila monster to you. Exenatide is the first of a new class of drugs known as "incretin mimetics" that can enhance your blood glucose control
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.03.2006
|
| 500 |
|
|
|a Date Revised 03.12.2018
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Hypoglycemic Agents
|2 NLM
|
| 650 |
|
7 |
|a Peptides
|2 NLM
|
| 650 |
|
7 |
|a Venoms
|2 NLM
|
| 650 |
|
7 |
|a Glucagon-Like Peptide 1
|2 NLM
|
| 650 |
|
7 |
|a 89750-14-1
|2 NLM
|
| 650 |
|
7 |
|a Exenatide
|2 NLM
|
| 650 |
|
7 |
|a 9P1872D4OL
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Diabetes self-management
|d 1998
|g 23(2006), 1 vom: 20. Jan., Seite 36, 39-40
|w (DE-627)NLM098190385
|x 0741-6253
|7 nnns
|
| 773 |
1 |
8 |
|g volume:23
|g year:2006
|g number:1
|g day:20
|g month:01
|g pages:36, 39-40
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 23
|j 2006
|e 1
|b 20
|c 01
|h 36, 39-40
|